Insulin Manufacturers, PBMs To Face US House Subcommittee Grilling On Drug Pricing

Executives from Eli Lilly, Novo Nordisk and Sanofi, as well as representatives from the three largest pharmacy benefit managers, will testify before the House Energy and Commerce Committee’s Subcommittee on Oversight and Investigations April 10; patients, professional organization representatives and academics at an April 2 hearing said they want to know why insulin prices remain out of reach for many diabetics.  

Autumn Capital Hill Panorama

More from Pricing Debate

More from Market Access